Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the "Company") determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.

Pursuant to the Employment Agreement, dated February 16, 2022, between the Company and Mr. Hassard (the "Employment Agreement"), which is filed as Exhibit 10.24 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and is incorporated herein by reference, subject to Mr. Hassard's execution of a release of claims in favor of the Company, its affiliates and their respective officers and directors, Mr. Hassard will be entitled to receive the payments and benefits associated with a termination without cause, as set forth in the Employment Agreement.